Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in outpatient adults with COVID-19
NL-OMON49040Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoints: Change from baseline in nasopharyngeal SARS-CoV-2 viral load on Day 3 and PCR result status on Day 3. Started Apr 2020; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49040.